Bank of New York Mellon Corp Reduces Stake in Autolus Therapeutics plc (NASDAQ:AUTL)

Bank of New York Mellon Corp lessened its position in shares of Autolus Therapeutics plc (NASDAQ:AUTL) by 8.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,673,994 shares of the company’s stock after selling 156,527 shares during the quarter. Bank of New York Mellon Corp owned 0.63% of Autolus Therapeutics worth $3,934,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Dumont & Blake Investment Advisors LLC bought a new stake in shares of Autolus Therapeutics during the 4th quarter valued at about $35,000. Arkadios Wealth Advisors purchased a new position in shares of Autolus Therapeutics in the fourth quarter worth approximately $47,000. Capstone Investment Advisors LLC bought a new stake in Autolus Therapeutics during the third quarter valued at approximately $51,000. Avanza Fonder AB bought a new position in Autolus Therapeutics in the fourth quarter worth approximately $75,000. Finally, Bellevue Group AG raised its position in Autolus Therapeutics by 27.7% in the third quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after acquiring an additional 9,000 shares during the period. Institutional investors own 72.83% of the company’s stock.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research report on Monday, January 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $10.40.

Autolus Therapeutics Trading Down 1.6 %

Autolus Therapeutics stock opened at $1.79 on Wednesday. Autolus Therapeutics plc has a 12-month low of $1.68 and a 12-month high of $6.63. The firm has a market capitalization of $476.31 million, a price-to-earnings ratio of -1.48 and a beta of 2.07. The firm has a 50 day moving average of $2.06 and a 200 day moving average of $2.95.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.